Channel Therapeutics Revamps Stock Structure
Channel Therapeutics Corporation, an innovative biotechnology firm, recently announced a transformative change in its stock structure that is set to enhance its visibility and valuation in the market. Based on its commitment to pioneering non-opioid pain treatments, the company has decided to execute a 10-for-one reverse stock split.
Purpose of the Reverse Stock Split
The primary aim of this reverse stock split is to elevate the market price of its common stock. This strategic move is essential for satisfying the initial listing requirements of the NYSE American, especially as the company is poised to merge with LNHC, Inc. This merger, coupled with an attractive financial backing of approximately $50 million from notable investors, marks a significant period of growth for Channel Therapeutics.
Details of the Stock Split
Approved by stockholders, the reverse stock split, effective before the market opens, is intended to streamline shares. Following the split, every ten shares will be converted into one, which will reduce the total outstanding shares. This transition is designed to leave each stockholder’s ownership percentage intact while simplifying the share structure.
Impact on Shareholders
Stockholders need not worry about any action on their part. All shares held in book-entry will automatically adjust to reflect the new equity value. Fractional shares will be rounded up, ensuring every stockholder retains a valuable stake in the company. The current stock symbol will change to reflect the upcoming merger, transitioning from "CHRO" to "PTHS" following the successful completion of the proposed transactions.
The Strategic Merger with LNHC, Inc.
The merger is not just a routine business adjustment; it represents a concerted effort by Channel Therapeutics to bolster its pipeline of innovative pain management solutions. The company has a unique focus on treating chronic and acute pain using its proprietary therapies targeting the sodium ion-channel known as NaV1.7.
Future Developments and Plans
Upon completion of the merger, Channel Therapeutics aims to increase its operational scope and research capabilities to address unmet needs in pain management. Investors and stakeholders can anticipate more comprehensive updates as the merger progresses and the company continues its commitment to developing effective therapeutic solutions.
Contacting Channel Therapeutics
As the changes unfold, Channel encourages shareholders to stay informed and engaged. For further inquiries, stockholders can reach out to the Nevada Agency and Transfer Company (NATCO). This dedicated team will assist shareholders with any concerns or questions regarding their stocks.
Company Overview
Channel Therapeutics is at the forefront of biotechnology, aiming to redefine how pain is treated. By focusing on non-opioid, non-addictive treatments, the company is committed to improving quality of life for individuals suffering from various pain conditions. To learn more about ongoing developments, visit their official website.
Frequently Asked Questions
What is the purpose of the reverse stock split?
The reverse stock split aims to increase the per-share market price of Channel Therapeutics' common stock to meet NYSE listing requirements.
How will the reverse stock split affect my shares?
Every ten shares will convert into one share, but shareholders’ percentage ownership will remain unchanged.
What is the new stock symbol after the merger?
After the merger, the stock symbol will change from "CHRO" to "PTHS".
When will the reverse stock split take effect?
The reverse stock split is expected to be effective before market open on a specified date.
How can I get more information regarding my stocks?
You can contact the Nevada Agency and Transfer Company (NATCO) for assistance related to your stock ownership.
